third quarter of 2007, HemaBio produced a net loss of approximately $300,000
Management estimates that the Company will report a loss from discontinued operations in the fourth quarter of 2007 of up to $1,000,000 related to the closure of HemaBio.
Company will recognize a goodwill impairment loss in the third quarter of 2007 equal to the total value of goodwill created as a result of the acquisition of HemaBio, or $4,259,000.
From Previous 8-k: Total debt related to Teragenix acquisition 2.5M.
Market Data 
Markets 
AI
